Glenmark Pharmaceuticals Limited
NYSE
Glenmark Pharmaceuticals Limited's latest marketcap:
As of 06/06/2025, Glenmark Pharmaceuticals Limited's market capitalization has reached $5.23 B. According to our data, Glenmark Pharmaceuticals Limited is the 3128th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 5.23 B |
| Revenue (ttm) | 1.57 B |
| Net Income (ttm) | 122.04 M |
| Shares Out | 282.2 M |
| EPS (ttm) | 0.43 |
| Forward PE | 26.05 |
| Ex-Dividend Date | 09/13/2024 |
| Earnings Date | 05/23/2025 |
Glenmark Pharmaceuticals Limited's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/06/2025 | ₹448.76 B | -1.51% |
| 12/31/2024 | ₹454.07 B | 88.44% |
| 12/29/2023 | ₹240.96 B | 101.33% |
| 12/30/2022 | ₹119.68 B | -19.75% |
| 12/31/2021 | ₹149.14 B | 7.1% |
| 12/31/2020 | ₹139.25 B |
Company Profile
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, along with its subsidiaries, is a global pharmaceutical company engaged in the development, manufacturing, and sale of generics, specialty products, and OTC pharmaceutical products. The company operates in key markets including India, North America, Latin America, Europe, and other international regions.
Therapeutic Areas & Product Offerings
The company provides a diverse range of branded and generic formulations across multiple therapeutic areas:
- Dermatology
- Respiratory
- Oncology
- Cardiology
- Diabetic
- Gynecology
- Gastroenterology
- Anti-infective
These products are available in various dosage forms, including complex injectables, biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays.
Key Pipeline Products
- ISB 2001 – A BCMA x CD38 x CD3 trispecific antibody in Phase 1 trials for relapsed/refractory multiple myeloma.
- ISB 1442 – A CD38 x CD47 bispecific antibody in Phase 1 trials for multiple myeloma and acute myeloid leukemia.
- GRC 65327 – A Cbi-b inhibitor in pre-clinical study for solid tumors.
- ISB 880 – An IL-1RAP antagonist monoclonal antibody in Phase 1 trials for autoimmune diseases.
- ISB 830 – A telazorlimab OX40 antagonist antibody in Phase 2 trials for atopic dermatitis.
Commercial Products
The company also offers Ryaltris nasal spray, a treatment for seasonal allergic rhinitis.
Company Background
Founded in 1977, Glenmark Pharmaceuticals is headquartered in Mumbai, India.
Frequently Asked Questions
-
What is Glenmark Pharmaceuticals Limited's (NSE-GLENMARK) current market cap?As of 06/06/2025, Glenmark Pharmaceuticals Limited (including the parent company, if applicable) has an estimated market capitalization of $5.23 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Glenmark Pharmaceuticals Limited (NSE-GLENMARK) rank globally by market cap?Glenmark Pharmaceuticals Limited global market capitalization ranking is approximately 3128 as of 06/06/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.